前列腺特异性膜抗原PET/CT中非增强CT成分在外周带前列腺癌检测中的作用
回顾性分析50例经活检证实的前列腺癌患者与50例同期因非前列腺恶性肿瘤行PET/CT的男性对照,评估非增强CT检测外周带前列腺癌的可行性。PSMA avid病灶平均HU为40.1±6.2,高于病例正常外周带28.2±7.0和对照27.7±5.8;ROC曲线分析显示平均HU≥35为阈值时,敏感度和特异度分别为86%和90%(AUC 0.88)。作者认为常规非增强CT可检测临床显著前列腺癌,放射科医生应常规寻找并报告这些发现。
要点
- PSMA avid病灶平均HU为40.1±6.2,高于正常外周带(病例28.2±7.0,对照27.7±5.8)。
- 平均HU≥35检测前列腺癌的敏感度86%、特异度90%(AUC 0.88)。
- 高级别与非高级别前列腺癌的平均HU值无显著差异。
核心结论
- 常规非增强CT扫描上检测临床显著前列腺癌是可能的,放射科医生应常规寻找并传达这些发现,以促进进一步检查和早期检测。
研究设计与样本
- 回顾性分析纳入2019年4月至2022年3月间50例经活检证实的前列腺癌患者(治疗前接受分期全身PSMA/CT)和50例同期因非前列腺恶性肿瘤行PET/CT的随机选取成年男性对照;两名读者独立测量病例正常外周带、中央带及相应PSMA avid病灶的HU值。
关键影像表现/征象
- 病例与对照的正常外周带平均HU值无显著差异。
- 病例PSMA avid病灶平均HU为40.1±6.2,高于病例正常外周带28.2±7.0和对照正常外周带27.7±5.8,差异有显著性。
- 高级别前列腺癌与非高级别前列腺癌的平均HU值无显著差异。
诊断标准与关键数值
- ROC曲线分析显示,病例与对照间检测前列腺癌的平均HU阈值为≥35,敏感度86%、特异度90%,AUC 0.88。
临床应用与阅片要点
- 作者认为常规非增强CT扫描上检测临床显著前列腺癌是可能的。
- 作者建议放射科医生应常规寻找并传达这些发现,以促进进一步检查和早期检测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The aim of this study was to look for feasibility of non-contrast CT (NCCT) in detecting peripheral zone prostate cancer (PCa).
METHODS: A retrospective analysis included 50 biopsy-proven PCa patients between April 2019 and March 2022 who underwent staging whole body prostate-specific membrane antigen (PSMA)/CT prior to treatment. The control subjects were 50 randomly selected adult male patients who underwent PET/CT for non-prostate malignancy during the same time period. Two readers independently calculated the Hounsfield unit (HU) of normal peripheral zone, central zone, and corresponding PSMA avid focus in cases.
RESULTS: No significant difference was seen in the mean HU value of normal peripheral zone between cases and controls. Significant difference in the mean HU was seen between the PSMA avid focus in cases (40.1 ± 6.2) and normal peripheral zone of cases (28.2 ± 7.0) and controls (27.7 ± 5.8). No significant difference was found between the mean HU values of high-grade PCa and non-high-grade PCa. Receiver operating characteristic (ROC) curve analysis revealed a mean HU cut-off of ≥35 for detecting PCa with a sensitivity and specificity of 86% and 90%, respectively, between cases and controls (AUC 0.88).
CONCLUSION: Detection of clinically significant PCa is possible on routinely performed NCCT scans. Radiologists should routinely look for and convey these findings to facilitate further work-up and early detection of PCa.
ADVANCES IN KNOWLEDGE: Our study adds to the knowledge that NCCT scans performed for unrelated indications can serve as a screening tool for clinically significant PCa.
引用
- Aggarwal P, Krishna Kumar RG, Das CJ, et al. Role of non-contrast CT component of prostate-specific membrane antigen PET/CT scan in the detection of peripheral zone prostate cancer. Br J Radiol. 2024. PMID: 38263835. doi:10.1093/bjr/tqad009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。